source
- Syndax halts development of Niktimvo after Phase 2 failure in IPF trialSyndax announced it is stopping work on its experimental drug Niktimvo for idiopathic pulmonary fibrosis (IPF) after the compound did not meet its primary endpoints in a placebo-controlled Phase 2…
- Bristol Myers reports two Phase 3 successes for fibrosis and RayzeBio drugBristol Myers Squibb announced Monday that two of its late-stage trials have met primary endpoints. The first trial involved its fibrosis program, where the experimental therapy demonstrated the e…